Home › Funds › Tower Research Capital LLC (TRC) › GSK

Tower Research Capital LLC (TRC) position in GSK

GSK PLC · Health Care

Tower Research Capital LLC (TRC) reported holding 463,125 shares of GSK (GSK PLC) in its Q2 2026 13F filing — a position valued at US$24.3M, representing 0.59% of its reported portfolio and ranking #29 among its reported holdings. Tower Research Capital LLC (TRC) has disclosed GSK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)463.12K sh
Reported value held$24.28M
Portfolio Weight0.59%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tower Research Capital LLC (TRC)'s GSK position evolved

Tower Research Capital LLC (TRC) first disclosed a stake in GSK in Q3 2023 at 717 shares (US$26K). The position peaked in Q2 2026 at 463,125 shares, worth US$24.3M. Across 12 filings, Tower Research Capital LLC (TRC) increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 463,125 shares valued at US$24.3M — an increase of 87,131 shares quarter over quarter.. Notable position changes include a 2430% increase in Q1 2025 (shares were roughly flat over the following quarter), a 549% increase in Q3 2025 (shares rose 14% over the following quarter), a 1040% increase in Q4 2025 (shares rose 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 717 $25.99K New
Q4 2023 3.79K $140.61K Add
Q1 2024 9.22K $395.09K Add
Q2 2024 29.14K $1.12M Add
Q3 2024 25.05K $1.02M Reduce
Q4 2024 586 $19.82K Reduce
Q1 2025 14.83K $574.40K Add
Q2 2025 3.10K $119.04K Reduce
Q3 2025 20.11K $867.95K Add
Q4 2025 229.21K $11.24M Add
Q1 2026 375.99K $20.75M Add
Q2 2026 463.12K $24.28M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GSK and 13F data

GSK (GSK PLC) is a Health Care company. 23 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.32B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GSK

All GSK fund holders →

FAQ

How long has Tower Research Capital LLC (TRC) held GSK?

Tower Research Capital LLC (TRC) has disclosed GSK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Tower Research Capital LLC (TRC)'s current position in GSK?

As of Q2 2026, Tower Research Capital LLC (TRC) holds 463.12K shares of GSK (GSK PLC), valued at $24.28M, representing 0.59% of its reported portfolio and ranking #29.

Has Tower Research Capital LLC (TRC) been buying or selling GSK?

In the latest 13F filing (Q2 2026), Tower Research Capital LLC (TRC) increased its position in GSK. The position peaked in Q2 2026 at 463.12K shares.

Which other funds hold GSK?

Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 23 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.